"From this work we conclude that Th17 cells may be implicated in the clinical effects of CTLA4 blocking monoclonal antibodies, and further study of their role in treatment-induced toxicities may help in elucidating how toxicities and responses may be differentially modulated with this mode of therapy."
Source:CTLA4 blockade increases Th17 cells in patients with metastatic melanoma.
Since I had a inflamatory response, I need to futher investagate the Th17 cells.
Jimmy B
No comments:
Post a Comment